Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:		NEW ASSIGNMENT	NEW ASSIGNMENT			
NATURE OF CONVEYANCE:		ASSIGNMENT				
CONVEYING PARTY	DATA					
		Name	Execution Date			
Advanced Phytonics	Limited		06/17/2005			
Liquidators			06/17/2005			
RECEIVING PARTY I	ΟΑΤΑ					
Name: Glaxo Group Limited						
Street Address:	Berkeley Avenue					
City:	Greenford, Middlesex					
State/Country:						
Postal Code:	UB6 0NN					
Application Number:		09319241				
Property Type Number						
		10394016				
Application Number:		10130204				
Application Number:	104	194962				
CORRESPONDENCE	E DATA					
Fax Number:	(610)270-52	253				
Correspondence will	. ,	il when the fax attempt is unsucce	essful.			
Phone: 610-270-5017						
Email:	US_CIPKOP@GSK.com					
Correspondent Name						
Address Line 1: Address Line 2:	709 Swedeland Road					
Address Line 2: Address Line 4:	CIP UW2220 King of Prussia, PENNSYLVANIA 19406					
ATTORNEY DOCKET		PB61489				
NAME OF SUBMITTE	:K:	Dara L. Dinner PATENT				
500325975 REEL: 019629 FRAME: 09						

Total Attachments: 5 source=Assignment#page1.tif source=Assignment#page3.tif source=Assignment#page4.tif source=Assignment#page5.tif



Dated 17 June 2005

Advanced Phytonics Limited (in liquidation) (1)

and

Glaxo Group Limited (2)

and

Gary Edgar Blackburn

David Leighton Cockshott (3)

US PATENT ASSIGNMENT

Linklaters

One Silk Street London EC2Y 8HQ

Telephone (44-20) 7456 2000 Facsimile (44-20) 7456 2222

Ref L-060925/Y Liyanage

PATENT REEL: 019629 FRAME: 0981 This Assignment is made on 17 June 2005 between:

- (1) Advanced Phytonics Limited (in liquidation) whose registered office is at bwc business solutions, 8 Park Place, Leeds LS1 2RU (company registration number 02950612) ("APL");
- (2) Gary Edgar Blackburn and David Leighton Cockshott both of bwc business solutions, 8 Park Place, Leeds LS1 2RU ("the Liquidators"); and
- (3) Glaxo Group Limited whose registered office is at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (company registration number 00305979) ("Glaxo").

Whereas:

- (A) APL is the registered proprietor of or applicant for the Patents.
- (B) The Liquidators were appointed as liquidators of APL on 21 February 2005.
- (C) APL has agreed to assign to Glaxo such right, title and interest in the Patents as APL may have and may lawfully assign.
- (D) The Liquidators are parties to this Assignment for the purposes only of taking the benefit of the exclusions of personal liability contained in it.

It is agreed as follows:

1 Interpretation

In this Assignment, unless the context otherwise requires:

"Patents" means the patent and patent applications particulars of which are set out in the Schedule and all patents granted from such patent applications, and all amendments, divisional applications, continuations, continuations-in-part, patent term extensions and geographical extensions in patent protection based on such patents and patent applications.

2 Assignment

- 2.1 In consideration of the sum of £18,400 paid by Glaxo to APL (receipt of which is hereby acknowledged by APL), APL hereby assigns to Glaxo:
 - 2.1.1 such right, title and interest in the Patents as APL may have and may lawfully assign, with the intent that any patent granted pursuant to any application assigned under this Assignment should be granted in the name of and vest absolutely in Glaxo; and
 - 2.1.2 all rights of action arising or accrued in relation to the Patents including, without limitation, the right to take proceedings and to seek and recover damages and seek other remedies for all past infringements.
- 2.2 No covenants for title shall be implied in this Assignment.

3 General

3.1 Glaxo acknowledges that it places and has placed no reliance whatsoever on any representations, agreements, statements or undertakings (oral or in writing) made or alleged to have been made by or on behalf of APL or the Liquidators or any of their

PATENT REEL: 019629 FRAME: 0982 respective employees, agents or representatives on or prior to the date of execution and delivery of this Assignment.

3.2 Glaxo hereby acknowledges to and agrees with the Liquidators and each of them that any personal liability upon either or both of them under this agreement and whether arising in contract or tort or both or by reference to any other remedy or right and in whatever jurisdiction or forum is hereby expressly excluded.

4 Law and Jurisdiction

- 4.1 This Assignment shall be governed by and construed in accordance with English law.
- **4.2** The parties irrevocably agree that the courts of England are to have exclusive jurisdiction to settle any dispute which may arise out of or in connection with this Assignment. The parties irrevocably submit to the jurisdiction of such courts and waive any objection to proceedings in any such court on the ground of venue or on the ground that proceedings have been brought in an inconvenient forum.

In witness whereof this Assignment has been entered into on the date stated at the beginning.

SIGNED on behalf of Advanced Phytonics Limited (in liquidation) by one of the Liquidators (as its agent without personal liability) in the presence of: Witness's signature

Name Address FLAT IA, THE MILL, COBIN LANCE, HELKMONDWIKE, WEI3 4BX SVE CARRENIGE

A05122755/0.2/27 May 2005

SIGNED by one of the Liquidators on behalf of both of them in the presence of: Witness's signature Name SVE CALLENTER.

Address

FLAT IA, THE MILL, IDIGIN LAME, HELKMONDMIKE, WEI3 48X.

SIGNED by

on behalf of Glaxo Group Limited in the presence of:

Witness's signature

Name

Address

failing, (Peter Giddings) Panes (Ralph Weiker) Glexa Smith Kline 980 Great West Road Brent Ford Millerex TW8 965 Great Britain

Schedule – The Patents

Country	Applicaton Number	Title of Invention	Filing Date	Priority Number/Date	Status
US	09/319,241	Materials Treatment	08.12.1997	9625417.2/06.12.1996 9717121.9/12.08.1997	Granted 03.06.2003
US	10/394,016	Materials Treatment	24.03.2003	9625417.2/06.12.1996 9717121.9/12.08.1997	Pending
US	10/130,204	Method for the production of particles	15.11.2000	9927011.8/16.11.1999	Pending
US	10/494,962 PCT/GB02/05017	Method for the production of particles	07.11.2002	0126716.0/07.11.2001	Pending